Lumito establishes Scientific Advisory Board with leading international experts in drug development, pathology, and oncology
Lumito has established a Scientific Advisory Board (SAB) to primarily support its ongoing commercialisation and, in the longer term, to strengthen the company’s strategic efforts toward a product for clinical use. The board comprises globally recognised experts in pathology, diagnostics, oncology, digitalisation, and drug development, with extensive experience spanning academia, healthcare, and the pharmaceutical industry.
The first meeting of Lumito’s Scientific Advisory Board will take place on Monday, 9 June 2025, and will focus on go-to-market strategies and applications within drug development.
“Establishing a Scientific Advisory Board is a strategically important step for Lumito. It provides us with access to unique expertise, experience, and an international network. I am very much looking forward to our first meeting on Monday and further discussions on direct applications of our solution in drug development. To accelerate our commercialisation journey, we have chosen to focus our first SAB meeting on strengthening and expanding the market presence of Scizys following its launch. In the future, I also see this advisory forum playing a key strategic role in identifying opportunities for clinical applications,” says Sanna Wallenborg, CEO of Lumito.
The SAB will contribute expertise in areas such as go-to-market strategy for new biomarkers, AI integration, and drug development. The combined experience and authority of the board members reinforce Lumito’s position within advanced tissue analysis and opens doors to senior decision-makers.
Lumito’s Scientific Advisory Board consists of:
Chair: Paul Waring, MD, PhD – internationally recognised pathologist and expert in translational research, anatomical, molecular, and digital pathology. Former Executive Director at AstraZeneca and Vice President at Roche Diagnostics, with extensive experience in biomarker development and integrating pathology in drug research. Currently Director at Translational Pathology Consultation Services.
Mark Lackner, PhD – leading oncology researcher with over 20 years of experience in translational science, biomarker strategy, and clinical development. Has held key positions at Genentech, IDEAYA Biosciences, and Zentalis Pharmaceuticals. Currently, Chief Scientific Officer at Firefly Biosciences.
Christian Ortiz-Villalón, MD, PhD, Executive MBA – pathologist and medical expert with deep experience in diagnostics, immuno-oncology, and digital pathology. Former global medical leader at AstraZeneca and Head of Diagnostics at Karolinska University Hospital. Currently Chief Medical Officer at Pathology Science and Head of Unit for Clinical Genetics, Pathology, and Molecular Diagnostics in Malmö, Region Skåne.
Jason Hipp, MD, PhD – anatomical pathology specialist and international pioneer in AI and digital health technology. Has held senior roles in data-driven pathology at AstraZeneca, Mayo Clinic, and Google/Verily. Currently CEO of JD Hipp Consulting.
Robert Gunnarsson, MSc, Executive MBA – strategist and product developer with solid experience from the diagnostics and life science industry. Has led global R&D initiatives at Thermo Fisher and driven transformation in spatial biology as CEO of Navinci Diagnostics. Currently CEO and founder of RoGu Consulting AB.
Read more about Lumito’s Scientific Advisory Board here.